Skip to content
Erektilní dysfunkce

Lecba Erektilní dysfunkce

Prozkoumejte dostupnou lecbu erektilní dysfunkce. Vse zahrnuje posouzeni nezavislym lekarem z EU, originalni leky z licencovanych lekaren a diskretni expresni doruceni.

2026-04-12 Léčba

Interested in Erektilní dysfunkce?

Complete a confidential health assessment reviewed by an independent EU-registered doctor.

Start Assessment

Erectile dysfunction léčba v Evropě

Erectile dysfunction (ED) — defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance — is one of the most prevalent male health conditions in Europe. Clinical studies estimate that ED affects approximately 19–52% of men between the ages of 40 and 70, with prevalence increasing markedly with age. Despite this, it remains significantly undertreated, with many men not seeking help due to embarrassment or a lack of accessible, confidential services.

ED can have both psychological and physiological causes, and in most cases the two are interrelated. Physiological factors include cardiovascular disease, diabetes, hypertension, hyperlipidaemia, hormonal imbalances, and neurological conditions. Lifestyle factors — including smoking, excessive alcohol consumption, obesity, and physical inactivity — are also established risk factors. Psychological contributors include performance anxiety, relationship difficulties, depression, and stress.

Critically, erectile dysfunction is recognised by European cardiovascular guidelines as a potential early marker of atherosclerosis and future cardiac events. Men presenting with new-onset ED should be evaluated for cardiovascular risk factors by a qualified clinician.

The first-line pharmacological treatment for ED is the class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors. These medications enhance the natural physiological pathway that produces an erection in response to sexual stimulation — they do not produce erections independently and are not effective without arousal. Four PDE5 inhibitors are currently EMA-approved: sildenafil, tadalafil, vardenafil, and avanafil.

Dostupné léčby

The following EMA-approved prescription medications are available for erectile dysfunction through EU-registered doctors. This comparison is provided for informational purposes only.

MedicationActive IngredientOnsetDurationNotes
SildenafilSildenafil citrate30–60 min4–6 hoursGeneric available; original Viagra
TadalafilTadalafil30–60 minUp to 36 hoursAlso available as daily 5 mg dose
VardenafilVardenafil HCl25–60 min4–6 hoursAlso available as orodispersible tablet
AvanafilAvanafil15–30 min6–12 hoursFastest onset; fewer food/alcohol interactions

Key distinctions:

  • Sildenafil: The most widely prescribed PDE5 inhibitor globally. Generic versions are available in most EU countries, making it typically the most cost-accessible option.
  • Tadalafil: The longest duration of action, earning it the informal name “the weekend pill.” The daily low-dose formulation (5 mg) allows spontaneous sexual activity without planning around timing.
  • Vardenafil: Similar efficacy profile to sildenafil. The orodispersible (dissolving tablet) formulation provides a discreet and convenient alternative to standard tablets.
  • Avanafil: The newest approved PDE5 inhibitor. Its faster onset and more selective mechanism may result in fewer side effects in some men, though individual response varies.

Jak získat léčba online

Prescrivia působí jako technologický zprostředkovatel: nepředepisujeme léky, nezaměstnáváme lékaře ani neprodáváme léky. Naše platforma spojuje pacienty s nezávislými lékaři registrovanými v EU, kteří mohou provádět důvěrná online zdravotní posouzení.

Postup je následující:

  1. Vyplňte zdravotní dotazník — Answer a structured set of medical questions covering the nature and duration of your ED, cardiovascular health, diabetes status, current medications (particularly nitrates or alpha-blockers), blood pressure, and lifestyle factors.

  2. Independent doctor review — An independent EU-registered doctor reviews your assessment. If a PDE5 inhibitor is clinically appropriate, the doctor may issue a prescription. If contraindications are identified, the doctor will explain and may suggest in-person follow-up.

  3. Předpis a vyřízení — If a prescription is issued, it is passed to a licensed EU pharmacy partner. Medication is dispensed and delivered discreetly to your address.

Důležité: Prescrivia nezaručuje, že bude předpis vystaven. Veškerá rozhodnutí o předepisování provádějí nezávisle kvalifikovaní odborní lékaři na základě Vašich individuálních klinických okolností.

Jak se srovnáváme

Prostřednictvím PrescriviaOsobní návštěva u lékaře
Dostupnost24/7 online assessmentSubject to appointment availability
Čekací dobaAssessment reviewed within hoursDays to weeks depending on location
Cestování nutnéNoYes
DůvěrnostFull GDPR-compliant data protectionStandard clinical confidentiality
Rozhodnutí o předpisuMade by independent EU-registered doctorMade by your GP
NákladyTransparent pricing displayed upfrontVaries by country and healthcare system

Note: ED associated with chest pain, severe cardiovascular disease, recent heart attack or stroke, or other complex comorbidities requires in-person specialist evaluation before any pharmacological treatment is considered. Prescrivia’s platform is designed for adults whose ED profile is suitable for remote assessment.

Zdroje

Lékařské informace na této stránce vycházejí z následujících zdrojů:

  • European Medicines Agency (EMA). Viagra/sildenafil — Summary of Product Characteristics. Available at: ema.europa.eu
  • Feldman HA, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. Journal of Urology. 1994;151(1):54-61.
  • Vlachopoulos CV, et al. Erectile dysfunction as a cardiovascular risk factor. European Heart Journal. 2013.

Tento obsah je pravidelně přezkoumáván s ohledem na aktualizované klinické pokyny. Je poskytován pouze pro informační účely a nepředstavuje lékařské poradenství. Vždy se poraďte s kvalifikovaným zdravotnickým pracovníkem o radě týkající se Vašich individuálních zdravotních okolností.

Frequently asked questions

Mohu získat Erektilní dysfunkce online v Evropě?
Přístup k přípravku můžete získat prostřednictvím online zprostředkovatelských platforem, které Vás spojí s nezávislými lékaři registrovanými v EU. Po vyplnění důvěrného zdravotního dotazníku lékař posoudí, zda je lék pro Vás klinicky vhodný.
Jaký je rozdíl between sildenafil and tadalafil?
Both are PDE5 inhibitors that work by the same mechanism, but they differ primarily in duration of action. Sildenafil works for approximately 4–6 hours and is typically taken 30–60 minutes before activity. Tadalafil lasts up to 36 hours and is also available as a once-daily low-dose formulation for spontaneous use.
Existují newer ED medications beyond sildenafil?
Yes. Vardenafil and avanafil are also EMA-approved PDE5 inhibitors. Avanafil has a faster onset than sildenafil — effects can begin within 15 minutes for some men. The most appropriate choice depends on individual health factors and preference, which the reviewing doctor will assess.
Je bezpečné to take ED medication with other medications?
PDE5 inhibitors are contraindicated with nitrate medications (commonly used for chest pain and heart conditions), as the combination can cause a dangerous drop in blood pressure. Other drug interactions also exist. This is why a medical assessment is required before any prescription is issued.
Can erectile dysfunction indicate a more serious health problem?
ED can be an early warning sign of cardiovascular disease, diabetes, hypertension, or hormonal imbalances. The health assessment includes questions to screen for relevant risk factors. If warranted, the reviewing doctor may recommend further investigation before or alongside treatment.
Prescrivia je pouze zprostředkovatelská platforma. Neposkytujeme lékařské služby, nepředepisujeme léčbu ani nevydáváme léky. Všechna lékařská rozhodnutí činí nezávislí lékaři registrovaní v EU. Všechny léky vydávají licencované lékárny v EU. Tato platforma usnadňuje spojení mezi pacienty a poskytovateli zdravotní péče.

Written by Prescrivia Editorial. Medical information sourced from European Medicines Agency (EMA), World Health Organization (WHO), and published clinical data.

This content is informational only and does not constitute medical advice.

Last updated:

Jste připraveni začít?

Vyplňte důvěrné zdravotní hodnocení za přibližně 3 minuty.